| Cat.No. | Name | Information |
|---|---|---|
| M1806 | PD 0332991 HCL | PD-0332991 HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. |
| M1974 | Roscovitine (Seliciclib) | Roscovitine is a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. |
| M2112 | LY2835219 mesylate | LY2835219 mesylate is an orally available inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM, respectively. |
| M1807 | SCH727965 (dinaciclib) | SCH727965 (Dinaciclib) is a potent and selective CDK inhibitor with IC50 values of 1, 1, 3 and 4 nM for CDK2, CDK5, CDK1 and CDK9, respectively. |
| M3519 | PHA-848125 | PHA-848125 is a potent, ATP-competitive CDK inhibitor for CDK2 with IC50 of 45 nM. It is >3-fold more selective for CDK2 than CDK1, 2, 4, 5, and 7. |
| M5228 | THZ1 | THZ1 is a covalent CDK7 inhibitor which has the unprecedented ability to target a remote cysteine residue located outside of the canonical kinase domain, providing an unanticipated means of achieving selectivity for CDK7. |
| M1710 | Flavopiridol | Flavopiridol (Alvocidib) is a competitive broad-spectrum CDK inhibitor with IC50 of 30,170,100 nM against CDK1, CDK2 and CDK4, respectively. |
| M6167 | Palbociclib | Palbociclib is a highly specific inhibitor of Cdk4 (IC50=11 nM) and Cdk6 (IC50=16 nM), having no activity against a panel of 36 additional protein kinases. |
| M5305 | RO-3306 | RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases. |
| M4889 | Ribociclib succinate (LEE011 succinate) | Ribociclib succinate (LEE011 succinate) is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
| M3890 | SU9516 | SU9516 is a selective CDK2 inhibtor with IC50 of 22 nM which is less potent for CDK1/CDK4(IC50=40/200 nM) and has no inhibition on PKC, EGFR, p38MAPK etc. |
| M3774 | Kenpaullone | Kenpaullone is potent inhibitor of CDK1/cyclin B and GSK-3β with IC50 values of 0.4 and 0.23 μM respectively. |
| M3729 | TAC-101 | TAC-101 is a retinobenzoic acid with potential antineoplastic activity. |
| M3687 | AT7519 hydrochloride | AT7519 hydrochloride is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM and induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition. |
| M3641 | XL413 | XL413 (BMS-863233) is a potent and selective cell division cycle 7 homolog (CDC7) kinase inhibitor with IC50 of 3.4 nM. |
| M3504 | BS-181 hydrochloride | BS-181 is a highly selective CDK7 inhibitor with IC50 of 21 nM. It is more than 40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9. |
| M3483 | Flavopiridol hydrochloride | Flavopiridol competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. |
| M3062 | TG003 | TG003 is a potent and ATP-competitive Cdc2-like kinase (Clk) inhibitor with IC50 of 20 nM, 200 nM, and 15 nM for Clk1, Clk2, and Clk4, respectively. No inhibitory effect on Clk3, SRPK1, SRPK2, or PKC. |
| M2913 | Palbociclib Isethionate | Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 2/3. |
| M2911 | Riviciclib hydrochloride (P276-00) | Riviciclib hydrochloride (P276-00) is an effective CDK inhibitor, inhibiting CDK9-CyclinT1, CDK4-cyclin D1, CDK1-Cyclinb with IC50 values of 20 nM, 63 nM, respectively. 79 nM. Riviciclib hydrochloride (P276-00) has anti-tumor activity against Cisplatin resistant cells. |
| M2893 | NU6027 | NU6027 is a potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with Ki of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors. |
| M2858 | ML167 | ML167 is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor with IC50 of 136 nM, >10-fold selectivity for closely related kinases Clk1-3 and Dyrk1A/1B. |
| M2590 | Purvalanol B | Purvalanol B(NG-95) is a cyclin-dependent kinase inhibitor with IC50 values of 6, 6, 9, > 10,000, and 6 nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, cdk4/cyclin D1 and cdk5-p35 respectively. |
| M2434 | BAY 1000394 | BAY 1000394 is an orally bioavailable pan-CDK inhibitor for CDK1/2/3/4/7/9 with IC50 of 5-25 nM. It also potently inhibits Aurora A, Clk2, ARK5, FGFR1, Flt3, and JAK2/3. Phase 1/2. |
| M2323 | BMS-265246 | BMS265246 is a potent and selective CDK inhibitor for CDK1/cyclin B and CDK2/cyclin E with IC50 of 6 nM and 9 nM, respectively. |
| M2322 | PHA-767491 | PHA-767491 is a potent ATP-competitive dual Cdc7/CDK9 inhibitor with IC50 of 10 nM and 34 nM, respectively. |
| M2239 | SB1317 | SB1317 (TG02) is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. |
| M2218 | Ribociclib (LEE011) | Ribociclib (LEE011) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is 1000 times less active against cyclin B/CDK1 complex. |
| M2065 | SNS-032 | SNS-032 (BMS-387032) is a potent and selective inhibitor of CDK 9, 2 and 7 with IC50 values of 4, 38 and 62 nM respectively. |
| M1810 | AZD5438 | AZD5438 is a novel, orally bioavailable inhibitor of cyclin-dependent kinase (CDK) 1, 2 and 9 (IC50 values are 16, 6 and 20 nM respectively). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
